DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for Inflammatory Bowel Disease: A multicentre consortium propensity score–matched analysisECCO'18 Vienna 2018
1
DOP011: Genotype-Phenotype association analysis of Inflammatory Bowel Disease in 6,395 East Asian subjects: Results from the international IBD Genetics ConsortiumECCO'18 Vienna 2018
1
DOP012: Disease demarcation in Ulcerative Colitis is associated with different patterns of gene expressionECCO'18 Vienna 2018
1
DOP013: An IBD associated variant in PTPN2 promotes inflammatory responses but enhances the anti-inflammatory effect of spermidineECCO'18 Vienna 2018
1
DOP014: Impact of genetic variation on gene and protein expression in Crohn’s DiseaseECCO'18 Vienna 2018
1
DOP015: Dysregulation of cell-type specific long ncRNA in the ileum of treatment naïve early onset Crohn DiseaseECCO'18 Vienna 2018
1
DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammationECCO'18 Vienna 2018
1
DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn's DiseaseECCO'18 Vienna 2018
1
DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s DiseaseECCO'18 Vienna 2018
1
DOP019: Immunomodulators reduce the risk of surgery and hospitalization in Crohn’s Disease in a prospective European population-based inception cohort – the Epi-IBD cohortECCO'18 Vienna 2018
1
DOP020:Thiopurine monotherapy still has a place in the treatment of patients with Mild-to-Moderate Crohn’s Disease in the biological eraECCO'18 Vienna 2018
1
DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s Disease: 10-year-follow-up data from the Swiss IBD cohort studyECCO'18 Vienna 2018
1
DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: A randomised controlled trialECCO'18 Vienna 2018
1
DOP025: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the OCTAVE clinical programmeECCO'18 Vienna 2018
1
DOP027: Efficacy and safety of an additional eight weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib eigth-week induction non-respondersECCO'18 Vienna 2018
1
DOP028: 2nd N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn’s Disease or Ulcerative ColitisECCO'18 Vienna 2018
1